Progress in the treatment of advanced gastric cancer
Z Song, Y Wu, J Yang, D Yang, X Fang - Tumor Biology, 2017 - journals.sagepub.com
Gastric cancer is one of the most common malignant tumors in the digestive system. Surgery
is currently considered to be the only radical treatment. As surgical techniques improve and …
is currently considered to be the only radical treatment. As surgical techniques improve and …
Oesophageal carcinoma
A Pennathur, MK Gibson, BA Jobe, JD Luketich - The Lancet, 2013 - thelancet.com
Oesophageal carcinoma affects more than 450 000 people worldwide and the incidence is
rapidly increasing. Squamous-cell carcinoma is the predominant form of oesophageal …
rapidly increasing. Squamous-cell carcinoma is the predominant form of oesophageal …
Circular RNA circ-RanGAP1 regulates VEGFA expression by targeting miR-877–3p to facilitate gastric cancer invasion and metastasis
J Lu, Y Wang, C Yoon, X Huang, Y Xu, J Xie, J Wang… - Cancer letters, 2020 - Elsevier
The biological functions of circular RNAs (circRNAs) in gastric cancer (GC) remain largely
unexplored. Here, we identified that circ-RanGAP1 was significantly upregulated in both GC …
unexplored. Here, we identified that circ-RanGAP1 was significantly upregulated in both GC …
LncRNA PVT1 promotes angiogenesis via activating the STAT3/VEGFA axis in gastric cancer
J Zhao, P Du, P Cui, Y Qin, C Hu, J Wu, Z Zhou… - Oncogene, 2018 - nature.com
Angiogenesis can aggravate gastric cancer progression. LncRNAs exert important roles in
regulating various cancer behaviors. However, the functions and mechanisms of lncRNAs in …
regulating various cancer behaviors. However, the functions and mechanisms of lncRNAs in …
Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial
M Ychou, V Boige, JP Pignon, T Conroy… - Journal of clinical …, 2011 - ascopubs.org
Purpose After curative resection, the prognosis of gastroesophageal adenocarcinoma is
poor. This phase III trial was designed to evaluate the benefit in overall survival (OS) of …
poor. This phase III trial was designed to evaluate the benefit in overall survival (OS) of …
Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study
A Ohtsu, MA Shah, E Van Cutsem, SY Rha… - Journal of clinical …, 2011 - ascopubs.org
Purpose The Avastin in Gastric Cancer (AVAGAST) trial was a multinational, randomized,
placebo-controlled trial designed to evaluate the efficacy of adding bevacizumab to …
placebo-controlled trial designed to evaluate the efficacy of adding bevacizumab to …
MET Amplification Identifies a Small and Aggressive Subgroup of Esophagogastric Adenocarcinoma With Evidence of Responsiveness to Crizotinib
JK Lennerz, EL Kwak, A Ackerman… - Journal of clinical …, 2011 - ascopubs.org
Purpose Amplification of the MET proto-oncogene in gastroesophageal cancer (GEC) may
constitute a molecular marker for targeted therapy. We examined a GEC cohort with follow …
constitute a molecular marker for targeted therapy. We examined a GEC cohort with follow …
Gastric cancer
V Catalano, R Labianca, GD Beretta, G Gatta… - Critical reviews in …, 2009 - Elsevier
Gastric cancer is one of the most common cancers and one of the most frequent causes of
cancer-related deaths. The incidence, diagnostic studies, and therapeutic options have …
cancer-related deaths. The incidence, diagnostic studies, and therapeutic options have …
Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer …
L Shen, J Li, J Xu, H Pan, G Dai, S Qin, L Wang… - Gastric cancer, 2015 - Springer
Background In the AVAGAST study, fluoropyrimidine and cisplatin plus bevacizumab did not
significantly improve overall survival (OS) versus fluoropyrimidine and cisplatin plus placebo …
significantly improve overall survival (OS) versus fluoropyrimidine and cisplatin plus placebo …
A phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal …
JW Valle, A Armstrong, C Newman, V Alakhov… - Investigational new …, 2011 - Springer
Purpose To evaluate the antitumor activity of SP1049C, a novel P-glycoprotein targeting
micellar formulation of doxorubicin, consisting of doxorubicin and two non-ionic block …
micellar formulation of doxorubicin, consisting of doxorubicin and two non-ionic block …